REVIEW  PROSTATE CANCER 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 March;63(1):29-36

DOI: 10.23736/S1824-4785.19.03155-8

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Prostate-specific membrane antigen radioligand therapy of prostate cancer

Mohsen BEHESHTI ^{1, 2}✉, Alexander HEINZEL ¹, Dirk von MALLEK ¹, Christian FILSS ¹, Felix M. MOTTAGHY ^{1, 3}

¹ Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany; ² Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University, Salzburg, Austria; ³ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targeted β- or α-radiation therapy.

KEY WORDS: Prostatic neoplasms - 177Lu-PSMA-617 - Radiotherapy